## **ERRATUM**



## **Erratum to: Durvalumab: First Global Approval**

Yahiya Y. Syed<sup>1</sup>

Published online: 10 October 2017

© Springer International Publishing AG 2017

## Erratum to: Drugs (2017) 77:1369–1376 DOI 10.1007/s40265-017-0782-5

The article "Durvalumab: First Global Approval", written by Yahiya Y. Syed, was originally published Online First without open access. After publication in volume 77, issue 12, pages 1369–1376 Springer Healthcare requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Springer Healthcare to test our procedures. Further details may be found at http://www.medengine.com/ Redeem/C898F06046BCED2D. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The online version of the original article can be found under doi:10. 1007/s40265-017-0782-5.

Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand